Dolores Schendel

Company: Medigene

Job title: Chief Scientific Officer

Seminars:

TCR-Guided Therapies to Match Individual Patient Needs 11:00 am

• We develop three TCR-guided modalities, TCR-T cells, TCR-NK cells, and TCR-TCEs, based on our 3S TCR technologies. • We assemble a library of 3S TCRs of different antigen specificity and HLA restriction to meet needs for more patients worldwide. • Our E2E Platform adds innovative solutions for improved development, safety and efficacy of our…Read more

day: Day 2

Industry Leaders’ Fireside Chat: A Commercial TCR-T & TCR Bispecific – What’s Next? 2:15 pm

• Reflecting on the past: celebrating the first TCR-T commercial approval and its impact on the field, along with novel clinical data • Determining the current state of play: discussing what challenges remain, the current funding environment and the priority for the field to outline present focus • What’s next? Discussing the potential for allogeneic…Read more

day: Day 1

Incorporating a Robust Tracking Method to Mediate Detection of TCRs In Vivo 5:00 pm

• Tagging engineered TCR-T cells to enable precise tracking of TCR molecules • Tracking cells in patients to support immune monitoring efforts • Harnessing learnings from cell tracking to further advance discovery and translational effortsRead more

day: Day 1